Intas Pharmaceutical limited, drug manufacturer based in Ahmadabad, India and it’s wholly owned subsidiary United States based Accord Healthcare Inc. has entered into settlement with pharmaceutical giant Hoffmann- La Roche to resolve pending patent litigation regarding XELODA tablets, generically known as Capecitabine tablets which are used in cure of metastatic breast and colorectal cancers. Hoffmann-La Roche had filed patent infringement suit against Accord Healthcare and Intas Pharmaceutical, upon its submission to the U.S. Food and Drug Administration (USFDA) of an Abbreviated New Drug Application (ANDA) for a generic version of Xeloda tablets.

As per the settlement and license agreement between the Hoffmann-La Roche and Intas, Roche will grant a license to Accord to enter into US market a generic version of Xeloda tablets ahead of its patent exclusivity period and the patent infringement suit instituted by the Roche will be dismissed. Further terms and conditions of the agreement are kept confidential.